|
|
|
|
| LEADER |
02845nam a22005175i 4500 |
| 001 |
978-981-10-4194-5 |
| 003 |
DE-He213 |
| 005 |
20170412095616.0 |
| 007 |
cr nn 008mamaa |
| 008 |
170412s2017 si | s |||| 0|eng d |
| 020 |
|
|
|a 9789811041945
|9 978-981-10-4194-5
|
| 024 |
7 |
|
|a 10.1007/978-981-10-4194-5
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a QA276-280
|
| 072 |
|
7 |
|a PBT
|2 bicssc
|
| 072 |
|
7 |
|a MBNS
|2 bicssc
|
| 072 |
|
7 |
|a MED090000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 519.5
|2 23
|
| 100 |
1 |
|
|a Ting, Naitee.
|e author.
|
| 245 |
1 |
0 |
|a Phase II Clinical Development of New Drugs
|h [electronic resource] /
|c by Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri.
|
| 264 |
|
1 |
|a Singapore :
|b Springer Singapore :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a XVII, 241 p. 25 illus., 17 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a ICSA Book Series in Statistics,
|x 2199-0980
|
| 505 |
0 |
|
|a Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials.
|
| 520 |
|
|
|a This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.
|
| 650 |
|
0 |
|a Statistics.
|
| 650 |
|
0 |
|a Management.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
1 |
4 |
|a Statistics.
|
| 650 |
2 |
4 |
|a Statistics for Life Sciences, Medicine, Health Sciences.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 650 |
2 |
4 |
|a Management.
|
| 700 |
1 |
|
|a Chen, Ding-Geng.
|e author.
|
| 700 |
1 |
|
|a Ho, Shuyen.
|e author.
|
| 700 |
1 |
|
|a Cappelleri, Joseph C.
|e author.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789811041921
|
| 830 |
|
0 |
|a ICSA Book Series in Statistics,
|x 2199-0980
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-981-10-4194-5
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SMA
|
| 950 |
|
|
|a Mathematics and Statistics (Springer-11649)
|
